BioInvent International AB (STO:BINV) to Release Q1 2008 Earnings April 10

BioInvent International AB (STO:BINV) will release the first quarter earnings for 2008 on Thursday, April 10. 

A Swedish biopharmaceutical company, BioInvent International is engaged in the research and development of antibody-based drugs to treat human immunodeficiency virus (HIV), arteriosclerosis, cancer, thrombosis and ophthalmic diseases.  The company is involved in the development of human antibodies and giving out licensing agreements.

The company is active in the co-development of intellectual property through strategic alliances with Genentech (NYSE:DNA), ThromboGenics Ltd. (EBR:THR), Celltec, XOMA (NASDAQ:XOMA), OrbusNeich, ImmunoGen (NASDAQ:IMGN) and other scientific advisors and companies.

BioInvent operates through its wholly owned subsidiary, BioInvent Finans AB.

View more Earnings related events or post your own on FindittEvents.